why choose us

First received: December 07, 2022

Clinical Trial: Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Clinical Stage II Esophageal Adenocarcinoma AJCC v8

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Trial of Chemotherapy, Pembrolizumab, and Propranolol in Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma Patients

Brief Summary: This phase II trial tests what effects the addition of propranolol to pembrolizumab and standard chemotherapy (mFOLFOX) may have on response to treatment in patients with esophageal or gastroesophageal junction cancer that cannot be removed by surgery and has spread to nearby tissue or lymph nodes (unresectable locally advanced) or has spread from where it first started (primary site) to other places in the body (metastatic).Propranolol is a drug that is classified as a beta-blocker.Beta-blockers affect the heart…

Read more